To determine what factors regulate gonocyte proliferation in newborn rats, we first examined the expression of several signal transduction molecules by immunocytochemistry in 3-day-old rat testis sections. We found that gonocytes specifically expressed the and isoforms of protein kinase (PK) C (PKC) and the phosphatidylinositol 3-kinase (PI 3-K). Because both the PKC and PI 3-K have been shown to play a role in platelet-derived growth factor (PDGF)-induced cell proliferation, we examined the effects of PDGF on gonocytes. For this, we developed a method to obtain highly purified and viable gonocytes in culture. After enzymatic digestion, differential adhesion, and two successive gradient fractionations, the gonocyte suspension obtained was over 90% pure, as assessed by light microscopy. The viability of cultured gonocytes exceeded 90% after 48 h in the presence of 2.5% FBS used as a survival factor. Immunodetection studies showed that isolated gonocytes expressed PKC, PI 3-K, and the PDGF receptor. Treatment with 10 ng/ml PDGF induced a 4-fold increase of bromodeoxyuridine incorporation into gonocytes (from 5% proliferative gonocytes under basal conditions to 20% in the presence of PDGF). Because neonatal Sertoli cells secrete high levels of the growth promoting steroid, 17␤-estradiol, we also tested its effect and found that it induced gonocyte proliferation at a level comparable with that of PDGF and that this effect was blocked by the estrogen receptor antagonist, ICI 164384. The combination of PDGF and estradiol, however, was not additive, suggesting that their effects were mediated by common molecular target(s). These results demonstrate that PDGF and estradiol activate gonocyte proliferation in vitro, suggesting that they may act as the physiological regulators of gonocyte development in vivo.
A BNORMAL proliferation and differentiation of gonocytes, the precursor cells of spermatogonia and spermatogenesis, have been associated with reproductive pathologies such as testosterone biosynthetic defect (1) and cryptorchidism (2) . Moreover, most testicular tumors are believed to arise from malignant fetal gonocytes (3) . Thus, the understanding of gonocyte development may be important in the management of these diseases and for the full comprehension of the spermatogenic process.
Early studies have determined that gonocytes go through two phases of proliferative activity, one in the embryo and the other at neonatal days 3 and 4, at which point, gonocytes migrate from the center to the periphery of the seminiferous cords and further differentiate into type A spermatogonia (4 -6) . It was demonstrated in organ cultures of newborn rat testis that both the reentry into proliferation and the relocation of gonocytes occur in the absence of extratesticular influences, suggesting that intratesticular factors, probably produced by Sertoli cells, control these events (4) . A few molecules already have been reported to affect gonocyte proliferation, such as thyroid hormone (7) , thymulin (8) , and the Mü llerian inhibiting substance (9) .
It has been reported recently that the fibroblast growth factor-2 (FGF2) exerts a proliferative effect and that leukemia inhibitory factor and ciliary neurotropic factor exert a survival effect on gonocytes cocultured with Sertoli cells (10, 11) . However, the interpretation of these results is limited because the two cell populations (gonocytes and Sertoli cells) were mixed, making it difficult to identify the target cell on which these agents act.
To overcome the problems inherent to the use of Sertoligonocyte cocultures, we decided to examine the regulation of purified gonocyte proliferation. We first examined what type of signal transduction molecules were expressed in neonatal gonocytes, as a way to determine what agents may be involved in their proliferation, and found that gonocytes expressed the PKC and the phosphatidylinositol 3-kinase (PI 3-K). The PKC belongs to a group of atypical PKCs that are not activated by Ca ϩϩ and diacylglycerol (12) and has been shown to be involved in cell mitosis (13) (14) (15) . Similarly, the PI 3-K, which catalyses the phosphorylation in position 3 of the inositol ring of phosphoinositides (16) , is an active component of the mitotic cascade of various cell types (17) . Moreover, these two kinases have been shown to be activated by platelet-derived growth factor (PDGF) (15, 18) . It has been suggested that Sertoli cells produce PDGF (19) . Neonatal rat Sertoli cells also are known to secrete high amounts of 17␤-estradiol (20) , which is a growth promoting agent (21) . Thus, we decided to study the effect of PDGF and estradiol on the proliferation of purified gonocytes. These experiments revealed that both PDGF and estradiol stimulate gonocyte proliferation.
Materials and Methods Animals
Sprague Dawley rat pregnant mothers or newborn male pups were purchased from Charles Rivers Laboratories (Wilmington, MA). Male pups, from the day of birth (day zero) to day 7 after birth, were killed by CO 2 inhalation and decapitation.
Purification and culture of gonocytes
The method used here is adapted and modified from that of Van Dissel-Emiliani et al. (22) . After collection, testes from 40 -50 pups (3 days old) were decapsulated, cut in small fragments, and incubated with 0.7 mg/ml type IV collagenase (Sigma Chemical Co., St. Louis, MO) and 0.2 mg/ml type III testicular hyaluronidase (Sigma) for 30 min in RPMI medium containing an antibiotic/antimycotic solution of 100 U/ml penicillin, 100 mg/ml streptomycin, and 0.25 mg/ml fungizone (Biofluids, Rockville, MD) at 37 C. After sedimentation, the first digest, which contained no gonocytes, was discarded, and the fragments were further incubated with 0.25% trypsin-1 mm ethylenediaminetetraacetate (GIBCO-BRL, Gaithersburg, MD) and 0.15 mg/ml DNase I (Boerhinger Mannheim, Indianapolis, IN) for 30 min. The digestion was then stopped by addition of FBS (GIBCO-BRL or Irvine Scientific, Santa Ana, CA). The cell suspension was filtered through 47-m nylon mesh (Small Parts Inc., Miami Lakes, FL) to discard large cell aggregates and fragments. The cells were quantified using a hemacytometer, where the gonocytes were easily identified by their large size. Because no specific marker is available to characterize gonocytes (10) , their size and morphology were used as criteria to quantify them during the whole purification procedure. The cell pellet, which contained 1-2% gonocytes (1.5 Ϯ 0.3 ϫ 10 6 gonocytes vs. 86 Ϯ 6 ϫ 10 6 Sertoli and other small cells in average), was resuspended in 240 ml RPMI containing 5% FBS, plated in 150 mm culture plates (15-20 ϫ 10 6 total cells per plate), and cultured overnight in 5% CO 2 atmosphere at 37 C. After 20 h culture, the floating cells (containing an average of 1.3 Ϯ 0.1 ϫ 10 6 gonocytes vs. 33 Ϯ 3 ϫ 10 6 other cells, corresponding to 4 -10% gonocytes) were collected, centrifuged, and resuspended in 3 ml serum-free RPMI. This suspension was then applied on a 2-4% BSA (Sigma) STAPUT gradient (23) . After 2 h sedimentation by gravity, 30 fractions of 2 ml were collected, and the cells were counted in a hemacytometer. The fractions containing the most gonocytes (as judged by their morphology and large size) were pooled and centrifuged. The cell pellet (0.6 Ϯ 0.1 ϫ 10 6 gonocytes vs. 1.2 Ϯ 0.2 ϫ 10 6 small cells in average) was resuspended in 1 ml RPMI containing 0.1% BSA and applied on a 10-ml density gradient made of 5-27% Nycodenz (GIBCO-BRL). After centrifugation, two major bands of cells were visible in the gradient, which was collected in 5 fractions. This additional step allowed the removal of most of the small cells still present (which were mostly dead cells, as determined by trypan blue exclusion). The final cell suspension (in average 0.48 Ϯ 0.02 ϫ 10 6 gonocytes with a purity of 92 Ϯ 5%), was diluted at 20,000 cells/ml and was kept in culture in RPMI supplemented with 2.5% FBS and the antibiotic/antimycotic solution for 1-2 days at 37 C.
Electron microscopy
Gonocytes were fixed after centrifugation in a solution of 1% paraformaldehyde, 2% glutharaldehyde in PBS for 15 min and washed several times with PBS. The cells were then embedded in Epon-araldite and further processed, as we described previously (24) .
Immunocytochemistry
Day 19 fetuses (1 day before birth) and newborn male rats (day zero to 7) were killed and their testis dissected and fixed in 3.5% formaldehyde. After several washes in PBS, the tissues were embedded in Polyester wax (Gallard-Schlesinger Chemical Manufacturing Corp., Carle Place, NY) as described in Ref. 25 , with minor modifications. Briefly, the testes were dehydrated through a graded series of ethanol, incubated for 1 h at 38 C in 50% Polyester wax (vol/vol in ethanol), then for 1 h in 90% Polyester wax, and finally embedded in 90% Polyester wax and kept at 4 C. Sections of 5 m were cut with a microtome at 4 C, collected on egg albumin-coated slides, allowed to dry, and kept at 4 C until staining. For this, the sections were first dewaxed through a graded series of ethanol solutions, washed with PBS and water, and then permeabilized by a microwave heating process as described in Ref. 26 . The slides were immersed in 0.01 m citrate buffer, pH 6.0, and heated in a microwave for 30 min at high power (800W), allowed to cool slowly for 2 h at room temperature, and after a few PBS washes, the immunostainings were carried out. The sections were incubated with the primary antibodies diluted (1:50 to 1:250) in PBS containing 10% calf serum (PBS/CS) overnight at 4 C. These antibodies were: mAb anti-PKA (Transduction Laboratories, Lexington, KT); mAb anti-PKC isoforms ␣, ␤, ␦, ⑀, , ␥, and (Transduction Labs); polyclonal anti PKC (GIBCO-BRL); mAb antiphosphotyrosine residue (PY20; Transduction Labs), polyclonal antiphospholipase C ␥ (Upstate Biotech Inc., Lake Placid, NY), polyclonal antiphospholipase A 2 (Upstate Biotech Inc., Lake Placid, NY); mAb anti-PI 3-K (Transduction Labs); and polyclonal anti-PDGF type A/B receptor (UBI). After a few washes in PBS, the sections were incubated for 1 h with a secondary antibody (antirabbit or antimouse, depending on the host of the first Ab) coupled to peroxidase (Transduction Labs) diluted at 1:1000 in PBS/CS, followed by 1 h incubation with the substrate mixture for peroxidase (0.03% H 2 O 2 ϩ 0.2 mg/ml 3-amino-9-ethylcarbazole in 0.05 m Na acetate, pH 5.0; Sigma). As a negative control, the first antibody was omitted in the treatment of some slides, whereas a neutralizing peptide was added with the primary antibody in the case of the staining for the PKC. Moreover, some primary antibodies that did not detect any signal in gonocytes, but were positively staining other cell types in the sections, provided a good indication of the background staining for gonocytes. At the end of the reaction, the sections were counterstained with hematoxylin (Sigma), the slides further coated with Crystal-mount (Biomeda Corp., Foster City, CA) and dried at 80 C for 10 min, and coverslips were added using Permount (Fisher Scientific, Columbia, MD). The sections were examined with an Olympus microscope and photographs were taken.
For the immunostaining of cultured cells, the gonocytes were first collected by centrifugation, resuspended in 200 l fresh medium, then transferred onto microscopic slides by centrifugation on a Cytospin 2 centrifuge (Shandon, Pittsburgh, PA) for 5 min at 1000 rpm and allowed to dry overnight at 4 C. The cells were then fixed in 70% ethanol for 15 min and processed directly (no microwave treatment) for staining as described above. Some slides were treated directly with the secondary antibodies to determine the background staining.
In vitro study of gonocyte proliferation
The proliferative response of gonocytes was followed by determination of 5-Bromo-2Ј-deoxyuridine (BrdU) incorporation according to the manufacturer's recommendations (cell proliferation kit from Zymed Laboratories Inc., South San Francisco, CA). For this, the cells were incubated with a mixture of 30 g/ml BrdU and 3 g/ml 5-fluoro2Јdeoxyuridine, together with the agents to be tested, for 20 h at 37 C. The agents used were: 0.1-100 ng/ml PDGF (type BB, human recombinant), 0.1-10 m 17␤-estradiol, 2.5 ng/ml epidermal growth factor (EGF), 1 ng/ml nerve growth factor (NGF), 25 ng/ml aFGF, and 10 ng/ml bFGF (all purchased from Sigma); 100 m ICI 164384 (gift from Dr. Alan Wakeling, Zeneca Corp., Macclesfield, UK), in the presence of 2.5% FBS. The cells were cultured in the presence of FBS because preliminary experiments had shown that it improved the viability and responsiveness of the cells without changing significantly the basal level of proliferation. At the end of the incubation, the cells were collected and applied on slides by Cytospin as described above. After fixation in 70% ethanol for 15 min, the cells were stained using the biotinylated antiBrdU antibody, streptavidin-peroxidase, and 3,3Ј-diaminobenzidine tetrahydrochloride substrate mixture provided in the kit, following the manufacturer's protocol. Pictures were taken of each slide (usually 4) to visualize all the cells present in each sample. The number of positively stained gonocytes was determined and expressed as a percent of the total number of gonocytes (an average of 800 cells were scored for each sample). The results represent means Ϯ sem of two to six individual experiments, in which each condition was tested in duplicate. Statistical analyses were performed by ANOVA followed by the Student-New-man-Keuls and the Bonferroni multiple comparisons tests using the Instat 2 (v2.04) package from Graphpad Inc. (San Diego, CA).
Some proliferation experiments also were carried out on gonocytes isolated from 1-or 2-day-old rats using the same procedures described above. After purification, part of these cells was put back in culture on Sertoli cell monolayers from the same experiment grown in Supercell-8 well-tissue culture chambers (Fisher Scientific; Pittsburgh, PA), while others were kept as isolated cell suspensions. The gonocytes in coculture were incubated with or without 2.5% FBS, while 10 ng/ml PDGF or 1 m estradiol were added together with FBS on the isolated gonocytes. In both cases, BrdU was added for 20 h with the other agents. At the end of the incubations, the gonocytes in coculture were fixed in the chambers with ethanol, which were then transformed into microscopic slides by removal of their walls. The isolated gonocytes were collected on slides by cytospin as described before. Gonocyte proliferation was then examined as described above.
Immunoblot analysis
Isolated gonocytes were collected by centrifugation, washed twice with PBS, and solubilized in Laemmli buffer (27). After electrophoretic separation by SDS-PAGE on a 10% acrylamide gel (reagents and equipment from Bio-Rad Laboratories, Melville, NY), the proteins were transferred onto nitrocellulose membranes (Immobilon-NC, Millipore, Bedford, MA) at 0.9 amperes for 30 min using a Trans-Blot Cell (Idea, Corvalis, OR). Nonspecific adsorption of the antibodies was prevented by incubating the sheets in 5% milk. The blots were then treated for immunodetection of the PKC, PKC, PI 3-K, and PDGF receptor using the same antibodies and peroxidase reaction used for the immunocytochemistry, except that these reagents were diluted (1:250 to 1:1000 for the primary antibodies; 1:2000 for the secondary antibodies) in PBS/CS containing 0.02% Tween 20, and that a chemiluminescent peroxidase substrate (Western Blot Chemiluminescence kit from Dupont-NEN, Boston, MA) was used. Some blots were treated with nonspecific IgG, instead of the first antibody, to determine the background staining. A neutralizing peptide for the PKC antibody also was used as another negative control, whereas the identity of the bands recognized by the antibodies was compared with that obtained for positive control cell extracts.
Results

Determination of the signal transduction molecules present in gonocytes
Sections of testes collected in rats from the day before birth and the day of birth (day zero) up to 7 days of age were processed for immunodetection of a panel of molecules that belong to known signal transduction cascades, namely the PKA, several PKC isoforms (␣, ␤, ␦, ⑀, , ␥, , ), the phospholipases C␥ and A 2 , the PI 3-K, and tyrosine kinase activity (identified by detection of phosphotyrosine residues (P-tyr) on proteins). As shown in Fig. 1 , A-E, only 3 of the molecules studied were expressed strongly by the gonocytes: the PKC, PKC, and the PI 3-K. The phospholipase A 2 was detectable in some gonocytes. The localization of P-tyr-proteins in gonocytes was difficult to ascertain, because it gave a strong signal at the lateral and apical borders of the Sertoli cells that are tightly apposed to the gonocyte plasma membranes. All of the other molecules were not expressed or their expression was below detection levels in gonocytes (see Table 1 ), although some were clearly present in other cell types, validating the antisera reactivity and the immunostaining procedure used. For example, PKA was expressed by the Sertoli cells, whereas the ␣ isoform of PKC was present in the peritubular and Leydig cells. The immunolocalization of most proteins was similar across the time-window studied. However, the cellular expression of the PKC was exclusively nuclear in the gonocytes at the day before birth, whereas it was mostly cytosolic at days 3 and 4 ( Fig. 1, A and B) . These results, together with the information available on the functions of PKC and PI 3-K, suggest that these enzymes could participate in the proliferative response of the gonocytes.
Viability and survival of the purified gonocytes in culture
To study the direct effects of PDGF and estradiol on gonocyte proliferation, we set up a method that would provide highly purified viable and functional gonocytes. After enzymatic digestion of the tissues, a large portion of the Sertoli cells was removed by an overnight adhesion to the culture plates at low cell density, whereas most of the gonocytes remained floating. We found that this step leads to a better separation of the cells through the BSA STAPUT gradient. Some of the BSA fractions collected were highly enriched in gonocytes (up to 70% purity), and the small cells still present at this step were taking up trypan blue, suggesting that they were dead cells. Most of these dead cells were eliminated by addition of a density gradient centrifugation, and the final cell suspension contained more than 90% gonocytes. The morphological characterization of the isolated gonocytes is illustrated in Fig. 2 by phase contrast and electron microscopy, and corresponds to what has been previously reported for gonocytes in vivo (6) . After 24 h in culture, 91% of the gonocytes were alive in RPMI medium, as showed by trypan blue dye exclusion. The addition of 2.5% FBS raised the survival to 97% and, after 48 h, 87% gonocytes were still alive. Numerous experiments were performed to substitute FBS with a chemically defined medium supplement such as a mixture of Insulin-Transferin-Selenium-BSA-linoletic acid (Collab. Biomed. Prod., MA) to culture the cells, but without success because the viability of the gonocytes in the presence of these supplements was not as good as that in the presence of low amounts of FBS (data not shown). Therefore, the culture medium was supplemented subsequently with 2.5% FBS as a survival factor. Also, in some preliminary experiments, some culture plates were precoated with extracellular matrix components (laminin, fibronectin, collagen, Matrigel) or poly-l-lysine to promote gonocyte adherence, but most of the cells remained floating or poorly attached to the substratum (data not shown). Thus, gonocytes were cultured as cell suspensions that had to be collected at the end of the incubations and applied onto microscopic slides by centrifugation on a Cytospin device as described above.
Immunolocalization of PDGF receptor, and PKC, PI 3-K, and P-tyr proteins in purified gonocytes
Because the presence of PKC and PI 3-K in gonocytes from the testis sections pinpointed PDGF as a potential proliferative agent, we then examined the expression of the PDGF receptor and that of PKC, PKC, PI 3-K, and P-tyr proteins in purified gonocytes kept in culture for 24 h. As shown in Fig. 3 , the PDGF receptor was present in some, but not all, gonocytes, whereas both PKC and PI 3-K were localized in the cytosol of most gonocytes. Subsequent immunolocalization of the PDGF receptor on testis sections from day-zero-to-7 pups further revealed that it was expressed in different cell types as a function of the develop- FIG. 1 . Expression of signal transduction molecules in rat testis sections examined by immunocytochemistry. Testes from three independent experiments for each age were processed for immunohistochemistry as described in Materials and Methods. The staining procedures were carried out on each set of testis, and each antibody was applied onto two to three sections each time. Representative areas from these sections were photographed. A, PKC (day 19 before birth); B, PKC (newborn day 3); C, PKC (day 3) in the presence of neutralizing peptide; D, PKC (day 3); E, PI 3-K (day 3); F, control day 3 (no primary antibody added); G, PDGF receptor (day 3); H, PDGF receptor (day 7) ment stage; whereas PDGF receptor was localized in the gonocytes and Sertoli cells during the first 5 days after birth, it was mostly expressed in the Leydig and myoid cells at day 7 (Fig. 1, G and H) . The presence of P-tyr proteins was evident, suggesting that at least part of the staining observed earlier in the testis sections was localized at the surface of the gonocytes. The PKC was expressed in a few cells only and at low levels (not shown).
The expression of these molecules in gonocytes also was examined by immunoblot analysis (Fig. 4) . Proteins of molecular size identical to that reported in the literature for these proteins were observed. In the cases of the PKC from brain tissue and the PI 3-K, the antibodies revealed one additional band of lower molecular weight than that of the enzyme, which may represent a breakdown product (especially for the PKC, because addition of the neutralizing peptide displaced that band too) or crossreactivity of the antibody with another molecule. These data further confirmed the results obtained by immunocytochemistry.
Effect of PDGF and estradiol on purified gonocyte proliferation
The proliferative response of the gonocytes was followed by determination of BrdU incorporation, which allows the visualization of each positive cell (Fig. 5, A and B) . We found that 2.5% FBS alone slightly improved the basal proliferation found in serum-free medium, probably by providing the necessary elements for survival and responsiveness of the cells in vitro. As shown in Figs. 5C and 6, the addition of PDGF stimulated gonocyte proliferation in a dose-dependent and biphasic manner, inducing a 4-fold increase at a maximal dose of 10 ng/ml. The addition of estradiol gave a similar biphasic response, with a maximal increase for a dose of 1 m (Figs. 5C and 7) . This effect was abolished by the addition of the antiestrogen, ICI 164384 (Fig. 5C ). As shown in Fig. 5C , the simultaneous addition of PDGF and estradiol had only a slight, insignificant, additive effect. When other growth factors were used at concentrations reported to be optimal in the literature (10, 28, 29), we found that EGF and NGF had no significant effect on gonocyte proliferation. Both a-and bFGF induced a slight, but not significant, increase in proliferation similar to that produced by low concentrations of PDGF.
Similar experiments carried out with purified gonocytes isolated from 2-day-old rats revealed that, although these cells were viable, they were not responsive to PDGF (Fig. 8A) or estradiol (not shown). However, when some of these purified cells were put back in culture on the Sertoli cell monolayers and further incubated with BrdU in the presence or absence of 2.5% FBS for 20 h, we found different results; the gonocytes were easily identified by their large size and round shape as compared with the small elongated Sertoli cells (Fig.  8B) . Even in the absence of FBS, a few gonocytes were clearly proliferative, as shown by their incorporation of BrdU (data not shown), and in the presence of FBS, a large proportion of gonocytes were proliferating (Fig. 8C) .
Discussion
The present study is the first one to examine the proliferation of testicular gonocytes in the absence of Sertoli cells. For many years, investigators have tried to determine the regulatory mechanisms of gonocyte proliferation (4 -6). They suggested that Sertoli cells probably were exerting control over this function, and a few factors have actually been shown to influence gonocyte proliferation (4 -10). However, all these studies were carried out on testis fragments or cocultures of Sertoli cells and gonocytes, making it impossible to demonstrate any direct effect on the gonocytes. Moreover, in our experience, it is very difficult to identify clearly the gonocytes that have been cocultured for few days with Sertoli cells, because their morphology changes as they flatten and elongate, whereas the appearance of some Sertoli cells changes also as they round up during division. To avoid these problems, we carried out our studies on purified gonocytes, thus demonstrating the direct action of molecules on gonocytes.
Considering that nothing was known about the signals acting on gonocytes and the signal transduction molecules present in these cells, and taking advantage of the availability of antibodies allowing the detection of most of the molecules involved in signal transduction pathways, it seemed that an initial screening of the gonocytes with such tools could give us indications of the type of regulatory mechanisms that are present and that may control gonocyte proliferation. Thus, we examined the expression of known signal transduction molecules in gonocytes from 3-day-old rat testis sections. These experiments revealed the presence in gonocytes of the and PKC and the PI 3-K. Both the and PKC are newly described atypical isoforms of PKC that share high sequence homology. Although nothing is yet known about the function of the PKC (30), a novel protein, the [Lambda]-interacting protein, recently has been shown to activate it (but not the PKC) (31), and it was proposed that this activation may be involved in cell proliferation. The PKC has been more widely studied, and its presence in gonocytes seemed very interesting because this kinase has been shown to be involved in cell mitosis; indeed, PKC was found to be associated with the mitotic apparatus of cells (13) . Another recent study described how the direct interaction of PKC with the Ras GTPase resulted in the activation of the serine/threonine kinase MEK (MAP kinase kinase) and its substrate the MAPK (mitogen-activated PK) (14, 15) , two kinases that belong to the transduction cascade of growth factors and trigger the transcription of genes associated with mitosis (32). There are only a few agents known to activate PKC: the ceramides, generated in cells stimulated by TNF␣ and interleukin-1 during inflammation (14) ; the phosphatidylinositol 3,4,5-triphosphate, product of the PI 3-K (33), which we also found in gonocytes; and the Ras GTPase (15) . Both the PI 3-K and Ras are involved in cell proliferation and are activated by PDGF (18) . The findings that the product of the PI 3-K and Ras were potent activators of the PKC suggest a functional Immunolocalization of signal transduction molecules in purified gonocytes after 24 h in culture. The cells were purified from 3-day-old rat testes as described in Materials and Methods, kept in culture for 24 h in the presence of 2.5% FBS, and then collected on microscopic slides by cytospin centrifugation. The immunostaining procedure was carried out as described in Materials and Methods, and representative cells were photographed. A, PKC; B, PI 3-K; C, P-tyr proteins; D, PDGF receptor; E, control (no primary antibody added).
link between these enzymes (33, 15). Such a relationship is suggested also by the data of Moscat et al., who found that a specific PI 3-K inhibitor abolished the activation of the PKC by PDGF (15) .
Another intriguing finding of our study is that the levels of expression of PKC were different in the in vivo and in vitro models used, because it seemed to be downregulated in vitro, whereas the expression of PKC under these conditions was not changed. It may be that the expression of the PKC isoform requires a constant signal from the Sertoli cells, whereas the maintenance of the isoform, once activated, is independent of the Sertoli cells.
The presence of proteins with phosphorylated tyrosine residues in gonocytes was consistent also with the involvement of a growth factor, such as PDGF, because its receptor is a tyrosine kinase, which, upon activation, phosphorylates itself and other proteins (34).
Altogether, these initial results pinpointed PDGF as a potential candidate for the activation of gonocyte proliferation. Another potential regulator studied here was the 17␤-estradiol, which had been shown to be secreted transiently at high levels by immature rat Sertoli cells during the same timeframe as that of gonocyte proliferation, although nothing is known about its function in this system (20) . The interaction of the estrogen and its receptor have been shown to have a growth promoting function in certain tissues such as breast and uterus (21, 35) .
Cell suspensions containing more than 90% pure and viable gonocytes were obtained by using a modified version of the existing methods. The identity of the gonocytes during the purification process was assessed by their size and morphology, as it has been done previously by other authors (4 -11) studying these cells. When the cells are in suspension, the difference in size between the gonocytes and the other cell types is obvious, the gonocytes appearing as very large round cells (twice as big as any other cell type) with big nuclei. These criteria are still the only ones available because no specific marker for gonocytes from new born rats have been yet identified. In addition, we have confirmed the identity of the purified gonocytes by transmission electron microscopy analysis. The identity of the small percentage (10%) of small-size, trypan blue-positive cells remaining at the end of the purification procedure is not clear. However, the observations that they are trypan blue positive and nonadherent excludes the possibility of these cells being live Sertoli cells. The gonocytes could be maintained in culture for at least 2 days without major effect on their viability in the presence of low amounts of FBS. High amounts of FBS have been reported to have a negative effect on early embryonic gonocytes, but not in gonocytes from 16-day-old embryos (36), whereas FBS has been shown to exert a positive effect on gonocyte proliferation in organ culture, probably through the Mü llerian inhibiting substance present in it (9, 37, 38) . Here, we found that low amounts of FBS actually improved the survival and responsiveness of newborn gonocytes.
Our results demonstrated that PDGF is able to activate the proliferation of isolated gonocytes in a dose-dependent manner. In contrast, neither EGF nor NGF had such an effect. The effects of EGF and NGF (which induced a 30 -60% increase over the basal level) were not found to be significant using 2 different statistical tests, although both EGF and NGF were used at concentrations reported to be optimal on testicular cells (28) and neurons (29), respectively. Both a-and bFGF seemed to have a small effect (inducing, respectively, 70 and 100% increases over the basal), which required higher concentrations than those used for PDGF. While this study was in progress, a report was published showing that FGF2 (bFGF) had a survival effect on Sertoli cells and gonocytes in coculture and that it seemed to stimulate gonocyte proliferation by 2-fold (10). However, it could not be excluded that the proliferative effect observed was the result of a primary effect of FGF2 on the Sertoli cells, inducing them to secrete factors that would, in turn, activate gonocyte proliferation. In this regard, immature rat Sertoli cells have been shown to express the FGF receptor type 1, which binds bFGF (39) , and bFGF has been shown by other investigators (40) to be mitogenic for these cells. Our present finding that bFGF is able to induce a small (2-fold) increase in purified gonocyte proliferation, in the same range as that found on gonocytesSertoli cell cocultures (10) , confirms that at least part of its effect observed on cocultures can be attributed to a direct effect on the gonocytes.
The present study showed that 17␤-estradiol also has a dose-dependent mitogenic effect on gonocytes, comparable with that triggered by PDGF. The inhibition of this effect by the estrogen antagonist, ICI 164384, suggested that the effect observed was mediated by the binding of the estrogen to its receptor, because this antiestrogen has been found to bind in the same region of the estrogen receptor as estradiol and to block the dimerization of the receptor and its subsequent binding to DNA (41) . Moreover, the fact that the effects of PDGF and estradiol were not additive or synergistic suggest that they may have common target molecule(s) in their pathways. In this regard, a recent study suggested that 17␤-estradiol was able to modulate the PDGF (type BB)-dependent uterine artery growth by both estrogen receptor and nonreceptor-mediated mechanisms (42), whereas another re- port described the activation of the estrogen receptor by the MAP kinase pathway (43) .
The proliferative effects observed were dependent on the developmental stage of the gonocytes because we found that gonocytes obtained from 1 or 2-day-old pups were viable, but unresponsive, to these agents (data not shown). The fact that the gonocytes obtained from 2-day-old rats were maintained for 1 night in coculture with Sertoli cells before their purification, and therefore were 3 days old when isolated from the Sertoli cells but still did not have the ability to proliferate, suggests that an irreversible change occurs in the gonocytes isolated from 3-day-old rats that allows them to be responsive to proliferative agents in the absence of Sertoli cells. Moreover, we found that the 2-day-old gonocytes could proliferate when kept in coculture with Sertoli cells for 1 more day, suggesting that the Sertoli cells themselves were changing during this time, probably acquiring the ability to secrete factors responsible for the induced changes in gonocyte responsiveness. These results were not surprising because Orth et al. had previously found that gonocyte proliferation occurred in the narrow time-frame of days 3 and 4 (5).
The facts that Sertoli cells have been shown to express the PDGF mRNA (19) and secrete estradiol in the neonatal period (20) suggest that they may constitute the source of these molecules in vivo. Thus, our next objective will be to determine whether the proliferative effects of PDGF and estradiol observed in vitro correspond to existing regulatory systems in vivo.
Our results validate the use of purified gonocytes as a model to study their proliferation and provide the means to study how gonocytes can progress from the stage of quiescent primordial germ cells to the stage of differentiation into spermatogonial stem cells. In addition, this model system also may provide the tool to understand the cellular and molecular mechanisms involved in pathological situations such as infertility and testicular tumorigenesis.
FIG. 8.
In vitro proliferation of purified gonocytes from 2-day-old rats. The cells were purified as described in Materials and Methods. Some gonocytes were then were cultured as isolated cells (A), whereas others were added back on Sertoli cell monolayers grown in Supercell culture chambers (B and C). In both cases, the proliferation was assessed using the BrdU incorporation technique as described above. FBS (2.5%) was added with BrdU in the cocultures, whereas FBS and 10 ng/ml PDGF were added to the isolated gonocytes. At the end of the incubations, the cocultures were fixed, the walls of the chambers removed, and the slides processed for staining. The isolated cells were collected on slides by cytospin centrifugation before the staining process. Isolated gonocytes stained for BrdU detection (A), cocultures stained with hematoxylin (B), and with the anti BrdU antibody (C); gonocytes are indicated by arrows. 
